Kargbo Robert B
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS Med Chem Lett. 2025 May 16;16(6):937-938. doi: 10.1021/acsmedchemlett.5c00265. eCollection 2025 Jun 12.
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.
N,N-二甲基色胺（DMT）和5-甲氧基-N,N-二甲基色胺（5-MeO-DMT）的创新制剂分别实现了肠胃外给药和鼻内给药。这些给药系统克服了生物利用度低和代谢迅速的局限性，提供起效迅速、持续时间短的治疗效果。这些组合物支持针对难治性抑郁症等精神疾病进行可控的迷幻干预，同时优化耐受性、可扩展性和临床实用性。
